Stemline Therapeutics IPO Research Information

Stemline Therapeutics IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Stemline Therapeutics, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Stemline Therapeutics	STML - NASDAQ	$10.00-$12.00	$10.00	$11.00	3.3 million	1/29/2013
Underwriter(s): Aegis Capital Corp
Co-Manager(s): Feltl & Co., Sunrise Securities
Industry: Health Care
Filing(s): Filed 2012-04-02

Stemline Therapeutics Quote & Chart - Click for current quote - STML

About Stemline Therapeutics (adapted from Stemline Therapeutics prospectus):
They are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells and tumor bulk.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "STML" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.